MRK · Merck & Co Inc
Price
Snapshot
50 fields · last close| Market Cap | $375.8B |
| P/E | 116.50 |
| Float | 2.47B |
| Beta | 0.14 |
| Volatility | 5.0% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 76 |
| Price | 150.44 |
| Change | −1.25% |
| Prev Close | 152.34 |
| Open | 152.80 |
| Day Low | 148.90 |
| Day High | 152.80 |
| Avg Vol | 12 |
| Avg $ Vol | $1.77B |
| 52W High | 156.92 |
| 52W Low | 77.58 |
| 52W Pos | 91.8% |
| From High | −4.13% |
| From Low | +93.92% |
| Max DD 1Y | −11.90% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | +4.52% |
| SMA 50 | +12.19% |
| SMA 200 | +27.36% |
| RSI (14) | 66.4 |
| Vol 30D | 40.7% |
| Vol 90D | 34.1% |
| 1Y Range | 78–157 |
| Daily bars | 506 |
| Perf Week | +1.87% |
| Perf Month | +18.71% |
| Perf Quarter | +26.68% |
| Perf Half Y | +31.25% |
| Perf Year | +80.97% |
| Perf YTD | +41.32% |
| Prev Day | −1.25% |
| Clavix | B+ |
| Debt / Eq | 0.94 |
| Curr Ratio | 1.54 |
| Int Cover | 0.4× |
| FCF Margin | 23.6% |
| Rev Growth | +5.1% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 7 / 15 |
What MRK does
Merck & Co., Inc. operates as a healthcare company worldwide.
It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.
The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands.
It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets.
The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Clavix risk grade
regraded every trading dayMRK grades B+, 76 of 100. Steadiest on Macro Resilience (65), most exposed on Sector Resilience (59, mixed). 0 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 7 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| MRK | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.14 | 0.43 |
| Volatilityannualized | 5.0% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −11.9% | — |
| Typical daily movemedian absolute daily change | 1.04% | — |
| Days beyond ±3%of the last 252 sessions | 229% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| MRK | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.14 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| MRK | |
|---|---|
| 1 week | +1.9% |
| 1 month | +18.7% |
| Year to date | +41.3% |
| 1 year | +81.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| MRK | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 6 Aug |
| Average score0 most bearish, 100 most bullish | 66 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 5 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 5 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| MRK | |
|---|---|
| Revenue growthyear over year | +5.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | MRK | Sector spread | Median |
|---|---|---|---|
| Beta | 0.14 | 0.43 | |
| Volatility | 5.0% | 10.7% | |
| Debt / equity | 0.94 | 0.94 | |
| Current ratio | 1.54 | 1.86 | |
| FCF margin | 23.6% | 20.8% | |
| Interest coverage | 0.4× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openMerck and Moderna's melanoma vaccine showed promising results, which the article says could lift the broader immunotherapy field and put healthcare ETFs in focus.
Merck's revenue grew at its usual pace over the past year while its stock outperformed its biggest peers, and the article attributes that gap to a run of clinical trial results that came in earlier than expected. The article body is short and offers little detail beyond these points.
Moderna and Merck announced on August 19, 2026, that their personalized mRNA cancer vaccine combined with Merck's Keytruda met the main goals of a Phase 3 trial (the final large-scale human test before a drug can be approved for regular use) for melanoma, a type of skin cancer. Moderna's stock jumped as much as 177%, adding $44 billion to its market value.
On August 19, 2026, Moderna and Merck said their personalized melanoma vaccine, intismeran, combined with Merck's Keytruda, met its main goals in a late-stage Phase 3 trial (a large final-round study before seeking approval) of 1,137 patients, lowering the risk of the cancer coming back or spreading compared with Keytruda used alone.
Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran, reduced the risk of melanoma recurrence and spread in a late-stage trial when used alongside Merck's immunotherapy drug Keytruda. The treatment met both its primary goal (lowering cancer recurrence) and secondary goal (preventing tumors from spreading), marking the first positive late-stage result for an mRNA cancer vaccine. The companies are already in discussions with regulators, and similar mRNA cancer vaccine approaches are being tested against lung, breast, and pancreatic cancers.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | A- | $671.0B | 31.85 | 0.21 | Compare |
| AZN | AstraZeneca PLC | B+ | $185.7B | 24.00 | 1.39 | Compare |
| PFE | Pfizer Inc | A- | $164.2B | 37.74 | 0.27 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $139.1B | 14.87 | 0.19 | Compare |
| LLY | Eli Lilly and Co | B | $1.09T | 40.31 | 0.43 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.